Demonstration of reversed IL-7R/IL-2R expression on CD3+ TIL toward IL-2R with increasing proximity to malignant prostatic cells (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Demonstration of reversed IL-7R/IL-2R expression on CD3+ TIL toward IL-2R with increasing proximity to malignant prostatic cells (Meeting abstract).

FASEB J; 7(3):A428 1993. Unique Identifier : AIDSLINE ICDB/94697227
Kramer G; Steiner G; Reinwald C; Schollhammer A; Binder S; Mehrawi M; Boltz G; Marberger M; Dept. of Urology, Univ. of Vienna, Austria

Abstract: To obtain exact information on the location and activation marker expression of individual lymphocyte subsets in situ and to arrive at inferences about their function, serial sections of 25 untreated cancer tissues were analyzed for intraepithelial (ie), periepithelial (pe) and perivascular (pv) CD3+ TIL/mm2. In general, CD3+ TIL ranged from 12/mm2 to 217/mm2 independently of tumor grade. 22.7% of CD3+ TIL were located pe within 0.05 mm of the epithelium, whereas the majority (65%) were more distant, only 8.3% being located ie and 3.9% pv. The CD4:CD8 ratio, which was 2.3:1 overall, showed a tremendous shift toward CD8+ cells of 1.08:1 in pe and 0.34:1 in ie areas. Overall TIL showed significant reactivity with anti-IL-7R (29.4/mm2) and anti-IL-2R (15.9/mm2) antibodies. The pattern of pe IL-7R+ (3.68/mm2) and IL-2R+ (2.86/mm2) cells reconfirms the drastic decrease seen in ie areas with IL-7R+ (0.03/mm2) and IL-2R+ (0.13/mm2) cells. Most interestingly, the ratio of IL-7R-:IL-2R-bearing cells showed a drastic shift toward IL-2R expression from 4.2:1 in pv to 0.22:1 in ie areas. These findings reflect the inability of T cells to invade glandular structures, and the loss of IL-7R expression within these immunosuppressed areas indicates the potential usefulness of IL-7R-bearing cells in immunotherapy of prostate cancer.

Keywords: Antigens, CD3/IMMUNOLOGY CD4-CD8 Ratio Human Immunotherapy Lymphocytes, Tumor-Infiltrating/METABOLISM Male Prostatic Neoplasms/IMMUNOLOGY/*METABOLISM/THERAPY Receptors, Interleukin/IMMUNOLOGY/*METABOLISM Receptors, Interleukin-2/IMMUNOLOGY/METABOLISM Tumor Cells, Cultured ABSTRACT
940530
M9450899

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .